Phaseline

Companies › ROKIT Healthcare

ROKIT Healthcare: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MAECM transplantation (Dr.INVIVO/AID REGEN/AI REGEN)
Autologous tissue-based regenerative procedure combining arthroscopic debridement, microfr
–Phase 4Cartilage Defects of the KneeJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07639424MAECM transplantation (Dr.INVIVO/AID REGEN/AI REGEN)Phase 4Cartilage Defects of the KneeOtherJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Mesoblast Aesculap Biologics Metcela OHB Pediatrics CoNextions Medical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.